Avid Bioservices Inc (CDMO): I would say that you are somewhat correc...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	86
Posts	12714
Boards Moderated	0
Alias Born	10/12/2010

biopharm

Re: ku post# 274068

Saturday, 10/01/2016 6:10:18 AM

Saturday, October 01, 2016 6:10:18 AM

I would say that you are somewhat correct in that IF all of Big Pharma wanted to exclude something it may work ....but we are now hearing and it is KNOWN that current SOC lacks on all accounts and 20-30% responders is shameful.

It is also KNOWN now that PS Targeting increases responders (as well as adaptive immunity) and too many people know about it now....no longer some little inside secret

Sean Parker knows.... Dr Soon knows ...hell, even VP Biden knows and Wolchok, MSK NCCN Merck....hmmm, all it takes is ONE group to take it on and the rest start to scramble and must decide

The time is now....for PS Targeting to enter into the big leagues.

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!